HIV-fertőzés: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CCR5 1
• CXCR4 0
• PD-1 2
• IL-15 1
• JAK 1
• STING 0
• GLP-1 2
• IL-17 0
• PD-L1 1
• TNF 0
• IL-6 0
• mTOR 1
• TP53 0
• NLRP3 0
• SGLT2 2
• STAT3 0
• AKT 0
• APOL1 0
• PCSK9 0
• PPAR 0
• CD40 1
• NRF2 0
• PI3K 0
• BCL-2 2
• CD19 1
• ERK 0
• HDAC 0
• HIF-1 0
• APOE 0
• BRD4 0
• FOXP3 0
• HSP90 0
• MAPK 0
• METTL3 0
• AMPK 0
• ATM 0
• BDNF 0
• CD20 0
• CD38 0
• CTNNB1 0
• FLT3 0
• HMGB1 0
• IL-1 0
• MET 0
• NMDA 0
• TIGIT 0
• VEGF 0
• ACE2 0
• ALK 0
• ANGPTL3 0
• AQP4 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CFTR 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  Development and Implementation of a Cost-Effective Diagnostic Algorithm to Reduce AIDS-Related Deaths among Hospitalized People with Advanced HIV Disease

  University of Minnesota· Minneapolis, Egyesült Államok· 55 114 USD awarded in fiscal year 2026· until 2030. okt.

• NIH NIAID · F32

  ENV GLYCOPROTEIN INCORPORATION AT HIV-1 ASSEMBLY SITES: STERIC REGULATION DRIVEN BY THE LONG CYTOPLASMIC TAIL

  University of Denver (Colorado Seminary)· Denver, Egyesült Államok· 89 476 USD awarded in fiscal year 2026· until 2027. okt.

• NIH NIDA · R34

  SMART: strengthening motivation and adherence to HIV prevention and treatment among people who use drugs in Atlanta

  Florida State University· Tallahassee, Egyesült Államok· 233 666 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NIAID · F31

  Human retrovirus assembly interplay with the actin cortex

  University of Minnesota· Minneapolis, Egyesült Államok· 48 621 USD awarded in fiscal year 2026· until 2029. szept.

• NIH NIDA · K23

  Implementing Human-Centered AI in Acute Care to Facilitate PrEP Delivery

  University of Alabama at Birmingham· Birmingham, Egyesült Államok· 200 232 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Comparative and entangled histories of AIDS care in Austria and Slovenia, 1980s–2000s (AIDScare)

  Universitaet Graz· Graz, Ausztria· EU contribution 230 185 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Immunometabolic Reprogramming via a Gut-derived Organoid Platform (IRGOP)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  BRIDGING RESERVOIR SCIENCE, INTEGRATED DRUG DISCOVERY, BIG DATA ANALYTICS, ARTIFICIAL INTELLIGENCE AND EPIDEMIOLOGY (BRIDGE-HIV)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 1 703 400 EUR· until 2030. szept.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  West African Network of Excellence for TB, AIDS and Malaria (WANETAM-4)

  European & Developing Countries Clinical Trials Partnership· Den Haag, Hollandia· EU contribution 12 751 885 EUR· until 2031. jún.· 14 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Defining the Landscape of Transcriptional Activity during HIV-1 Infection (DELTA-HIV)

  King's College London· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. máj.

10 of 2671 running projects, newest first. Listed amounts together: 2,1 Mrd USD + 81,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial

  NCT07081763· ANRS Maladies Infectieuses Emergentes· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 22
• Organoids 6
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 27
• Gene Expression Profiling 62
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 15
• Exome Sequencing 3
• Proteomics 37
• Metabolomics 33
• Mass Spectrometry 16
• Flow Cytometry 45
• Immunohistochemistry 15
• Xenograft Model Antitumor Assays 3
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 79
• Machine Learning 72
• Deep Learning 21
• Cohort Studies 426
• Genome-Wide Association Study 20

• Emergency Department Management of Body-Fluid Exposures Receiving Human Immunodeficiency Virus Post-Exposure Prophylaxis: Adherence to Australian Guideline Recommendations.

  Emerg Med Australas, 2026. dec.

• Weight Trajectories in Virally Suppressed People With HIV Compared With Matched People Without HIV, and Predictors of Weight Gain: A 3-Year Cohort Study From the US TRIO Healthcare Network.

  J Acquir Immune Defic Syndr, 2026. nov.

• Integrating HCV Testing and Treatment Into HIV Care: A Cohort Study of the HCV Care Cascade in Southwest China.

  Liver Int, 2026. nov.

• Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, by Chronic Liver Disease Status.

  J Acquir Immune Defic Syndr, 2026. nov.

• Prevalence and Predictors of Abnormal Cervical Cytology Among Women Living With HIV and Without HIV From the MACS/WIHS Combined Cohort Study.

  J Acquir Immune Defic Syndr, 2026. nov.

• Comorbidity burden and outcomes with long-acting cabotegravir plus rilpivirine in the RELATIVITY cohort.

  AIDS, 2026. okt.

• Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort.

  Clin Infect Dis, 2026. okt.

• Multimorbidity Trajectories and Hospitalization Risk Among People With HIV in Sub-Saharan Africa: A Longitudinal Analysis From the African Cohort Study.

  Clin Infect Dis, 2026. okt.

• Associations between biomarkers and clinical outcome in people hospitalized with HIV: a retrospective cohort.

  Rev Lat Am Enfermagem, 2026. okt.

• Understanding viral blips in people with HIV on antiretroviral therapy: a nationwide Swedish cohort study of 4,210 individuals.

  BMC Infect Dis, 2026. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.